EDSA vs. PTI, ONCT, CARM, CALC, RPHM, RMTI, ANEB, BLRX, KZR, and EQ
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Proteostasis Therapeutics (PTI), Oncternal Therapeutics (ONCT), Carisma Therapeutics (CARM), CalciMedica (CALC), Reneo Pharmaceuticals (RPHM), Rockwell Medical (RMTI), Anebulo Pharmaceuticals (ANEB), BioLineRx (BLRX), Kezar Life Sciences (KZR), and Equillium (EQ). These companies are all part of the "medical" sector.
Edesa Biotech (NASDAQ:EDSA) and Proteostasis Therapeutics (NASDAQ:PTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
Edesa Biotech presently has a consensus target price of $39.00, indicating a potential upside of 816.29%. Given Edesa Biotech's higher probable upside, research analysts plainly believe Edesa Biotech is more favorable than Proteostasis Therapeutics.
Proteostasis Therapeutics received 292 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 75.76% of users gave Edesa Biotech an outperform vote while only 59.03% of users gave Proteostasis Therapeutics an outperform vote.
Proteostasis Therapeutics' return on equity of -75.39% beat Edesa Biotech's return on equity.
In the previous week, Edesa Biotech had 4 more articles in the media than Proteostasis Therapeutics. MarketBeat recorded 4 mentions for Edesa Biotech and 0 mentions for Proteostasis Therapeutics. Edesa Biotech's average media sentiment score of 0.97 beat Proteostasis Therapeutics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the media.
Edesa Biotech has higher earnings, but lower revenue than Proteostasis Therapeutics.
5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 16.6% of Proteostasis Therapeutics shares are owned by institutional investors. 25.0% of Edesa Biotech shares are owned by company insiders. Comparatively, 4.8% of Proteostasis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Edesa Biotech has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Proteostasis Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.
Summary
Edesa Biotech beats Proteostasis Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edesa Biotech Competitors List
Related Companies and Tools
